15 results
Thumbnail

D2.475 - Treatment delay and likelihood of remission on omalizumab in chronic spontaneous urticaria: a real-world observational study

Thumbnail

D2.465 - Omalizumab Enhances Safety and Supports Completion of Oral Immunotherapy in High-Risk Patients

Thumbnail

D2.466 - More options for the treatment of Chronic Spontaneous Urticaria: Tezepelumab

Thumbnail

D2.467 - Management of Netherton syndrome and hereditary angioedema with concurrent biologic therapy: a novel case

Thumbnail

D2.468 - Real-world effectiveness and safety of dupilumab in pediatric atopic dermatitis: a retrospective cohort study

Thumbnail

D2.469 - Pre-switch perceptions of omalizumab biosimilar prefilled pen in pediatric allergy: a cross-sectional survey

Thumbnail

D2.472 - Immunology Innovation Program: Developing Antibodies Against Novel Targets Through Co-creation

Thumbnail

D2.474 - Use of Dupilumab as treatment for Eosinophilic Enteritis: a case report

Thumbnail

D2.476 - Mepolizumab Enables Meaningful Real-World Improvements in SNOT-22 and Smell Dysfunction in Chronic Rhinosinusitis with Nasal Polyps: Post Hoc Analysis of REALITI-N at 3 and 6 Months

Thumbnail

D1.200 - Allergenicity of profilin isoallergens from Korean melon

Thumbnail

D1.201 - Safety and Effectiveness of Subcutaneous Immunotherapy with Non-Homologous Aeroallergen Mixtures: A Real-World Study

Thumbnail

D1.206 - Local allergic rhinitis to birch pollen: a case of transient IgE+ plasmablast detection and successful sublingual immunotherapy

Thumbnail

D1.213 - Staphylococcus aureus enterotoxins in allergic rhinitis: impact on disease severity and molecular sensitization profile

Thumbnail

D1.216 - AIT prescription drivers: a factor analysis of data from the CHOICE survey

Thumbnail

D1.214 - Analysis of the time to achieve a maintenance dose of tree pollen allergen in specific immunotherapy of allergic rhinitis